Noor Alhuda Al-Karawi
Noor Alhuda Al-Karawi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Dominika Gacka
Szpital Morski Im. PCK, Gdynia, Poland
10 shared publications - Katarzyna Gondek
PIM MSWiA w Warszawie, Warsaw, Poland
10 shared publications - Magdalena Fidelis
Szpital Morski Im. PCK, Gdynia, Poland
10 shared publications - Maria Wojcieszek
Medical University of Warsaw, Warsaw, Poland
10 shared publications - Paulina Kędziorek
SPZOZ – ZZ im. Duńskiego Czerwonego Krzyża, Maków Mazowiecki, Poland
10 shared publications - Zuzanna Tanç
SPZOZ – ZZ im. Duńskiego Czerwonego Krzyża, Maków Mazowiecki, Poland
10 shared publications
Latest Publications
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
NIPAH VIRUS: CLINICAL PERSPECTIVES ON AN EMERGING PRIORITY PATHOGEN
The emergence of zoonotic viral diseases has significantly impacted public health, the global economy, and societal structures in recent years. The World Health Organization's 2024 updated R&D Blueprint report identifies infectious agents posing the greatest epidemiological threats. Among them is the Nipah virus (NiV), a highly lethal paramyxovirus naturally harboured by fruit bats, which typically causes severe respiratory distress and encephalitis in humans. Moreover, the NiV exhibits the capacity to infect a wide range of mammalian species, including livestock and domestic pets. The secretions and excretions of these animals can potentially serve as sources of human infection. This presents both a direct health risk and an indirect one, due to losses in agriculture and associated economic consequences. After the first outbreak in Malaysia (1998–1999), in addition to decontamination measures, mass culling of pigs was carried out. Although Malaysia has been declared free of NiV infection, new cases continue to emerge almost annually in Bangladesh and India, with the most recent reported in 2025. Given the current scale of human migration, the global nature of food transportation, and other facets of globalization, it is imperative to prepare for the potential spread of the disease of a magnitude similar to COVID-19. To date, no targeted therapies or vaccines have been approved. Given this situation, the primary objective of the present work is to raise awareness among clinicians regarding the characteristics and pathogenicity of NiV, as well as the practical aspects related to the recognition, diagnosis, and treatment of the infection.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessNIPAH VIRUS: CLINICAL PERSPECTIVES ON AN EMERGING PRIORITY PATHOGEN
The emergence of zoonotic viral diseases has significantly impacted public health, the global economy, and societal structures in recent years. The World Health Organization's 2024 updated R&D Blueprint report identifies infectious agents posing the greatest epidemiological threats. Among them is the Nipah virus (NiV), a highly lethal paramyxovirus naturally harboured by fruit bats, which typically causes severe respiratory distress and encephalitis in humans. Moreover, the NiV exhibits the capacity to infect a wide range of mammalian species, including livestock and domestic pets. The secretions and excretions of these animals can potentially serve as sources of human infection. This presents both a direct health risk and an indirect one, due to losses in agriculture and associated economic consequences. After the first outbreak in Malaysia (1998–1999), in addition to decontamination measures, mass culling of pigs was carried out. Although Malaysia has been declared free of NiV infection, new cases continue to emerge almost annually in Bangladesh and India, with the most recent reported in 2025. Given the current scale of human migration, the global nature of food transportation, and other facets of globalization, it is imperative to prepare for the potential spread of the disease of a magnitude similar to COVID-19. To date, no targeted therapies or vaccines have been approved. Given this situation, the primary objective of the present work is to raise awareness among clinicians regarding the characteristics and pathogenicity of NiV, as well as the practical aspects related to the recognition, diagnosis, and treatment of the infection.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
ONE PATHWAY, INFINITE POTENTIAL? THE FUTURE OF GLP-1 THERAPIES: A 2026 CLINICAL UPDATE
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have advanced from incretin-based therapies for type 2 diabetes to multifaceted treatments addressing obesity, cardiovascular disease, and emerging neuropsychiatric conditions. This review examines their physiological mechanisms, pharmacological profiles, and clinical outcomes based on data through early 2026. GLP-1 RAs mimic the incretin effect, enhancing insulin secretion, delaying gastric emptying, and modulating central reward pathways in the mesolimbic system. Approved agents like semaglutide and tirzepatide achieve 15-25% weight loss, reduce major adverse cardiovascular events by 12-26%, and show promise in heart failure with preserved ejection fraction and chronic kidney disease. Recent trials indicate potential in alcohol use disorder, with semaglutide reducing heavy drinking and cravings, though cognitive benefits in major depressive disorder remain unproven. Safety analyses from large cohorts (2024-2025) confirm no increased thyroid cancer risk (HR 0.81-0.93), and FDA reviews (2026) find no causal suicidality link. Overall, GLP-1 RAs bridge metabolic and behavioral health, supporting a unified view of energy regulation. Ongoing research on patient responders and targeted analogues will guide their integration into care for metabolic psychiatry, emphasizing balanced risk assessment.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessONE PATHWAY, INFINITE POTENTIAL? THE FUTURE OF GLP-1 THERAPIES: A 2026 CLINICAL UPDATE
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have advanced from incretin-based therapies for type 2 diabetes to multifaceted treatments addressing obesity, cardiovascular disease, and emerging neuropsychiatric conditions. This review examines their physiological mechanisms, pharmacological profiles, and clinical outcomes based on data through early 2026. GLP-1 RAs mimic the incretin effect, enhancing insulin secretion, delaying gastric emptying, and modulating central reward pathways in the mesolimbic system. Approved agents like semaglutide and tirzepatide achieve 15-25% weight loss, reduce major adverse cardiovascular events by 12-26%, and show promise in heart failure with preserved ejection fraction and chronic kidney disease. Recent trials indicate potential in alcohol use disorder, with semaglutide reducing heavy drinking and cravings, though cognitive benefits in major depressive disorder remain unproven. Safety analyses from large cohorts (2024-2025) confirm no increased thyroid cancer risk (HR 0.81-0.93), and FDA reviews (2026) find no causal suicidality link. Overall, GLP-1 RAs bridge metabolic and behavioral health, supporting a unified view of energy regulation. Ongoing research on patient responders and targeted analogues will guide their integration into care for metabolic psychiatry, emphasizing balanced risk assessment.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
THE EYE AS AN INTERFACE: HOW XR, AI AND AUTOMATION CHANGED OPHTHALMIC PRACTICE (2015–2025)
This review examines the integration of emerging digital technologies in ophthalmology to address global vision impairment affecting over 2.2 billion people, with a focus on scalability, equity, and sustainability amid rising age-related pathologies like AMD, glaucoma, and DR. Objectives: Synthesize evidence from 2015-2025 on xVR/AR, AI, teleophthalmology, robotics, and nanotechnology, evaluating clinical efficacy, economic viability, ethical implications, and environmental impact. Methods: Systematic literature search across PubMed, Scopus, IEEE Xplore, and Web of Science using Boolean keywords for targeted technologies. Inclusion: peer-reviewed studies with quantitative outcomes (e.g., visual acuity, AUC, CO2 reductions); exclusion: pre-2015, non-English, non-clinically validated works. Data extraction emphasized study design, interventions, outcomes, biases, and ethics. Key Findings: VR dichoptic therapy yields 1.8 logMAR improvements in amblyopia with 88% adherence, surpassing patching. AI achieves >90% sensitivity for DR screening, mitigated by generative models for bias. Teleophthalmology resolves 75% cases remotely, saving up to 176 kg CO2/patient. Robotics enable 5%); 3D bioprinting pioneers corneal implants. Conclusions: These technologies foster precise, decentralized eye care, but require addressing biases, regulations, and access barriers for equitable global impact.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessTHE EYE AS AN INTERFACE: HOW XR, AI AND AUTOMATION CHANGED OPHTHALMIC PRACTICE (2015–2025)
This review examines the integration of emerging digital technologies in ophthalmology to address global vision impairment affecting over 2.2 billion people, with a focus on scalability, equity, and sustainability amid rising age-related pathologies like AMD, glaucoma, and DR. Objectives: Synthesize evidence from 2015-2025 on xVR/AR, AI, teleophthalmology, robotics, and nanotechnology, evaluating clinical efficacy, economic viability, ethical implications, and environmental impact. Methods: Systematic literature search across PubMed, Scopus, IEEE Xplore, and Web of Science using Boolean keywords for targeted technologies. Inclusion: peer-reviewed studies with quantitative outcomes (e.g., visual acuity, AUC, CO2 reductions); exclusion: pre-2015, non-English, non-clinically validated works. Data extraction emphasized study design, interventions, outcomes, biases, and ethics. Key Findings: VR dichoptic therapy yields 1.8 logMAR improvements in amblyopia with 88% adherence, surpassing patching. AI achieves >90% sensitivity for DR screening, mitigated by generative models for bias. Teleophthalmology resolves 75% cases remotely, saving up to 176 kg CO2/patient. Robotics enable 5%); 3D bioprinting pioneers corneal implants. Conclusions: These technologies foster precise, decentralized eye care, but require addressing biases, regulations, and access barriers for equitable global impact.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
PRECISION MEDICINE FOR RYR1-RELATED MYOPATHIES: A COMPREHENSIVE REVIEW OF GENE EDITING, PHARMACOLOGICAL INTERVENTIONS, AND SOCIETAL IMPLICATIONS
Ryanodine receptor 1-related myopathies (RYR1-RM) constitute the most prevalent class of non-dystrophic congenital myopathies, representing a complex intersection of genetic heterogeneity, molecular pathology, and evolving therapeutic paradigms. Characterized by mutations in the RYR1 gene, these disorders manifest across a broad clinical spectrum ranging from static congenital weakness to life-threatening pharmacogenetic traits such as Malignant Hyperthermia Susceptibility (MHS). This review article provides an exhaustive synthesis of the scientific and societal landscape of RYR1-RM as of 2025. We provide a deep mechanistic analysis of the RyR1 channel's structure-function relationship, elucidated through recent cryo-electron microscopy breakthroughs that define the "leaky channel" pathophysiology. We critically evaluate the emerging pharmacological arsenal, including the landmark Phase 1b trial of the Rycal compound ARM210 (S48168), the novel application of epigenetic modulation via 5-aza-2'-deoxycytidine, and the repurposed utility of dantrolene and salbutamol. Furthermore, we dissect the frontier of precision genetic engineering, detailing the mechanics and efficacy of Prime Editing and Twin Prime Editing strategies, alongside the development of myotropic viral vectors (MyoAAV) designed to overcome the delivery barriers inherent to the massive RYR1 gene. Beyond the bench, this report integrates a rigorous social science perspective, analyzing the health economic frameworks (ICER, QALYs) that govern access to orphan drugs, the ethical dimensions of somatic gene editing for non-lethal disabilities, and the transformative role of patient advocacy in the rare disease ecosystem. This multidimensional review aims to serve as a foundational resource for clinicians, researchers, and policymakers navigating the complex transition from supportive care to disease-modifying precision medicine.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessPRECISION MEDICINE FOR RYR1-RELATED MYOPATHIES: A COMPREHENSIVE REVIEW OF GENE EDITING, PHARMACOLOGICAL INTERVENTIONS, AND SOCIETAL IMPLICATIONS
Ryanodine receptor 1-related myopathies (RYR1-RM) constitute the most prevalent class of non-dystrophic congenital myopathies, representing a complex intersection of genetic heterogeneity, molecular pathology, and evolving therapeutic paradigms. Characterized by mutations in the RYR1 gene, these disorders manifest across a broad clinical spectrum ranging from static congenital weakness to life-threatening pharmacogenetic traits such as Malignant Hyperthermia Susceptibility (MHS). This review article provides an exhaustive synthesis of the scientific and societal landscape of RYR1-RM as of 2025. We provide a deep mechanistic analysis of the RyR1 channel's structure-function relationship, elucidated through recent cryo-electron microscopy breakthroughs that define the "leaky channel" pathophysiology. We critically evaluate the emerging pharmacological arsenal, including the landmark Phase 1b trial of the Rycal compound ARM210 (S48168), the novel application of epigenetic modulation via 5-aza-2'-deoxycytidine, and the repurposed utility of dantrolene and salbutamol. Furthermore, we dissect the frontier of precision genetic engineering, detailing the mechanics and efficacy of Prime Editing and Twin Prime Editing strategies, alongside the development of myotropic viral vectors (MyoAAV) designed to overcome the delivery barriers inherent to the massive RYR1 gene. Beyond the bench, this report integrates a rigorous social science perspective, analyzing the health economic frameworks (ICER, QALYs) that govern access to orphan drugs, the ethical dimensions of somatic gene editing for non-lethal disabilities, and the transformative role of patient advocacy in the rare disease ecosystem. This multidimensional review aims to serve as a foundational resource for clinicians, researchers, and policymakers navigating the complex transition from supportive care to disease-modifying precision medicine.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
THE INVISIBLE INTRUDER: A REVIEW OF MICROPLASTICS ACCUMULATION IN HUMAN TISSUES AND IMPLICATIONS FOR PUBLIC HEALTH, WITH EMPHASIS ON REPRODUCTIVE HEALTH
Global plastic production has led to widespread environmental contamination, with synthetic polymers fragmenting into microplastics (MPs) and nanoplastics (NPs). These particles have been detected in human tissues, raising questions about their health effects. This narrative review synthesizes biomonitoring studies on MP/NP accumulation, with a focus on reproductive systems. Data from recent research show polymers in blood, lungs, placentas, breast milk, testes, and brain, linked to exposure routes such as inhalation and ingestion. The review examines potential translocation across barriers like the placenta and blood-brain barrier, as well as toxicity mechanisms, including endocrine-disrupting chemical release, oxidative stress via the Nrf2 pathway, and cellular disruption. In reproductive health, evidence indicates MP presence in ovarian follicular fluid and associations with reduced sperm quality, suggesting potential contributions to fertility trends. The review also addresses debates on neuro-accumulation and economic costs of related diseases. Findings highlight MPs as a public health concern, calling for policy measures and updated risk assessments.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessTHE INVISIBLE INTRUDER: A REVIEW OF MICROPLASTICS ACCUMULATION IN HUMAN TISSUES AND IMPLICATIONS FOR PUBLIC HEALTH, WITH EMPHASIS ON REPRODUCTIVE HEALTH
Global plastic production has led to widespread environmental contamination, with synthetic polymers fragmenting into microplastics (MPs) and nanoplastics (NPs). These particles have been detected in human tissues, raising questions about their health effects. This narrative review synthesizes biomonitoring studies on MP/NP accumulation, with a focus on reproductive systems. Data from recent research show polymers in blood, lungs, placentas, breast milk, testes, and brain, linked to exposure routes such as inhalation and ingestion. The review examines potential translocation across barriers like the placenta and blood-brain barrier, as well as toxicity mechanisms, including endocrine-disrupting chemical release, oxidative stress via the Nrf2 pathway, and cellular disruption. In reproductive health, evidence indicates MP presence in ovarian follicular fluid and associations with reduced sperm quality, suggesting potential contributions to fertility trends. The review also addresses debates on neuro-accumulation and economic costs of related diseases. Findings highlight MPs as a public health concern, calling for policy measures and updated risk assessments.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
THE HIDDEN COST OF FLEXIBILITY: MUSCULOSKELETAL DISORDERS, TECHNOSTRESS, AND SOCIAL ISOLATION IN THE ERA OF REMOTE WORK
The global shift to remote and hybrid work models from 2021 to 2025, comparable to the Industrial Revolution in scale, has entrenched flexibility while introducing unintended physiological, psychological, and sociological costs. This narrative review synthesizes data from the International Labour Organization, World Health Organization, Eurofound, and peer-reviewed literature (2020-2025) to analyze these externalities among college-educated workers. Drawing on the Global Survey of Working Arrangements (G-SWA), work-from-home stabilized at 1.27 days/week globally (27% of U.S. workdays), with regional disparities (e.g., 1.5-1.9 days in English-speaking economies vs. 0.5-1.0 in Asia) influencing exposure. The "Infinite Workday" (Microsoft, 2025) - characterized by 117 emails, 153 Teams messages, and 275 daily interruptions - exacerbates issues like Work-Related Musculoskeletal Disorders (WRMSDs, prevalence 61.2%-72%, e.g., neck pain 50.4%-58.9%) and Computer Vision Syndrome (CVS, pooled 69.0%, 95% CI 62.3-75.3). Psychologically, technostress (50-70% prevalence for techno-overload) and Zoom fatigue (40-70%) blur boundaries, while sedentary isolation elevates inflammation (CRP/IL-6) and depression risk (20-43%). Sociologically, women face double burdens (promotion gap 37% vs. 49% for men), Gen Z reports 27% loneliness, and individualism explains 29% WFH variance. Economically, costs include $380.9 billion U.S. MSK healthcare and $9.6 trillion global disengagement opportunity (Gallup, 2025). Without ergonomic (e.g., TuMeke's 42% injury reduction), policy ("Right to Disconnect" reducing stress 10-30%), and cultural interventions, flexibility's dividends risk erosion by chronic morbidity.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessTHE HIDDEN COST OF FLEXIBILITY: MUSCULOSKELETAL DISORDERS, TECHNOSTRESS, AND SOCIAL ISOLATION IN THE ERA OF REMOTE WORK
The global shift to remote and hybrid work models from 2021 to 2025, comparable to the Industrial Revolution in scale, has entrenched flexibility while introducing unintended physiological, psychological, and sociological costs. This narrative review synthesizes data from the International Labour Organization, World Health Organization, Eurofound, and peer-reviewed literature (2020-2025) to analyze these externalities among college-educated workers. Drawing on the Global Survey of Working Arrangements (G-SWA), work-from-home stabilized at 1.27 days/week globally (27% of U.S. workdays), with regional disparities (e.g., 1.5-1.9 days in English-speaking economies vs. 0.5-1.0 in Asia) influencing exposure. The "Infinite Workday" (Microsoft, 2025) - characterized by 117 emails, 153 Teams messages, and 275 daily interruptions - exacerbates issues like Work-Related Musculoskeletal Disorders (WRMSDs, prevalence 61.2%-72%, e.g., neck pain 50.4%-58.9%) and Computer Vision Syndrome (CVS, pooled 69.0%, 95% CI 62.3-75.3). Psychologically, technostress (50-70% prevalence for techno-overload) and Zoom fatigue (40-70%) blur boundaries, while sedentary isolation elevates inflammation (CRP/IL-6) and depression risk (20-43%). Sociologically, women face double burdens (promotion gap 37% vs. 49% for men), Gen Z reports 27% loneliness, and individualism explains 29% WFH variance. Economically, costs include $380.9 billion U.S. MSK healthcare and $9.6 trillion global disengagement opportunity (Gallup, 2025). Without ergonomic (e.g., TuMeke's 42% injury reduction), policy ("Right to Disconnect" reducing stress 10-30%), and cultural interventions, flexibility's dividends risk erosion by chronic morbidity.
- Open Access
- 6 July 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 83, 60689
Autism Spectrum Disorder in ICD-11: Diagnostic, Therapeutic and Identity - Related Implications of the Discontinuation of Asperger's Syndrome as a Separate Diagnosis
The reclassification of Asperger’s syndrome within DSM-5 (2013) and ICD-11 (2019) marked a pivotal moment in the diagnostic landscape of neurodevelopmental disorders. After three decades of being recognized as a distinct clinical entity, Asperger’s syndrome was merged into the broader autism spectrum disorder (ASD) category, triggering extensive debate over diagnostic precision, social identity, and clinical consequences. This review synthesizes evidence on the evolution of diagnostic criteria, with a focus on historical milestones (Kanner, Asperger, Wing) that shaped the conceptualization of autism and Asperger’s syndrome across successive DSM and ICD editions. A structured literature search (PubMed, Scopus, Google Scholar; 2005–2024) identified 92 peer-reviewed articles meeting inclusion criteria (English or Polish language, human studies, and clear reference to diagnostic transitions and their psychosocial or clinical impact). Special attention is given to the effects of reclassification on individuals’ identity, the risk of diagnostic loss—especially in those with mild or atypical profiles—and the evolving terminology debate. Findings indicate that approximately 10–15% of individuals previously diagnosed with Asperger’s syndrome no longer meet ASD criteria under DSM-5 and ICD-11, raising concerns about service access and psychological well-being. The review also discusses challenges in distinguishing ASD from personality disorders, the diagnostic implications of camouflaging behaviors, and future research directions aimed at refining assessment tools and supporting neurodivergent identity.
- 6 July 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 83, 60689
Open AccessAutism Spectrum Disorder in ICD-11: Diagnostic, Therapeutic and Identity - Related Implications of the Discontinuation of Asperger's Syndrome as a Separate Diagnosis
The reclassification of Asperger’s syndrome within DSM-5 (2013) and ICD-11 (2019) marked a pivotal moment in the diagnostic landscape of neurodevelopmental disorders. After three decades of being recognized as a distinct clinical entity, Asperger’s syndrome was merged into the broader autism spectrum disorder (ASD) category, triggering extensive debate over diagnostic precision, social identity, and clinical consequences. This review synthesizes evidence on the evolution of diagnostic criteria, with a focus on historical milestones (Kanner, Asperger, Wing) that shaped the conceptualization of autism and Asperger’s syndrome across successive DSM and ICD editions. A structured literature search (PubMed, Scopus, Google Scholar; 2005–2024) identified 92 peer-reviewed articles meeting inclusion criteria (English or Polish language, human studies, and clear reference to diagnostic transitions and their psychosocial or clinical impact). Special attention is given to the effects of reclassification on individuals’ identity, the risk of diagnostic loss—especially in those with mild or atypical profiles—and the evolving terminology debate. Findings indicate that approximately 10–15% of individuals previously diagnosed with Asperger’s syndrome no longer meet ASD criteria under DSM-5 and ICD-11, raising concerns about service access and psychological well-being. The review also discusses challenges in distinguishing ASD from personality disorders, the diagnostic implications of camouflaging behaviors, and future research directions aimed at refining assessment tools and supporting neurodivergent identity.
- Open Access
- 6 July 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 83, 60681
Understanding Postpartum Psychosis: Current Perspectives and Clinical Implications
Postpartum psychosis (PPP) is a rare but severe psychiatric condition that typically emerges within the first two weeks after childbirth, requiring immediate clinical intervention due to risks of suicide and infanticide. Despite its severity, PPP remains under-recognized in major diagnostic classifications such as the DSM-5 and ICD-10, complicating diagnosis and legal considerations. This review synthesizes current knowledge on PPP, including its epidemiology, multifactorial etiology, clinical presentation, and management strategies. Risk factors span genetic vulnerability, hormonal and immune dysregulation, sleep disruption, and psychosocial stressors. Diagnosis is often delayed due to stigma and lack of specific screening tools. Treatment includes a stepwise pharmacological approach using benzodiazepines, antipsychotics, lithium, and electroconvulsive therapy (ECT) for refractory cases, alongside psychosocial interventions. Lithium maintenance therapy has demonstrated significant efficacy in relapse prevention, while medication safety during lactation remains a key clinical concern. The review underscores the urgent need for standardized diagnostic criteria, greater public and professional awareness, and further research into the biological mechanisms underlying PPP. Timely detection and coordinated care can significantly improve outcomes for both mother and child.
- 6 July 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 83, 60681
Open AccessUnderstanding Postpartum Psychosis: Current Perspectives and Clinical Implications
Postpartum psychosis (PPP) is a rare but severe psychiatric condition that typically emerges within the first two weeks after childbirth, requiring immediate clinical intervention due to risks of suicide and infanticide. Despite its severity, PPP remains under-recognized in major diagnostic classifications such as the DSM-5 and ICD-10, complicating diagnosis and legal considerations. This review synthesizes current knowledge on PPP, including its epidemiology, multifactorial etiology, clinical presentation, and management strategies. Risk factors span genetic vulnerability, hormonal and immune dysregulation, sleep disruption, and psychosocial stressors. Diagnosis is often delayed due to stigma and lack of specific screening tools. Treatment includes a stepwise pharmacological approach using benzodiazepines, antipsychotics, lithium, and electroconvulsive therapy (ECT) for refractory cases, alongside psychosocial interventions. Lithium maintenance therapy has demonstrated significant efficacy in relapse prevention, while medication safety during lactation remains a key clinical concern. The review underscores the urgent need for standardized diagnostic criteria, greater public and professional awareness, and further research into the biological mechanisms underlying PPP. Timely detection and coordinated care can significantly improve outcomes for both mother and child.
- Open Access
- 30 June 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 82, 60580
Impact of Dietary Factors on Thyroid Function and Disorders
Thyroid health is intricately linked to nutritional status, as multiple micronutrients and dietary components modulate hormone biosynthesis, metabolism, and immune function. The increasing global prevalence of autoimmune thyroid disorders, particularly Hashimoto’s thyroiditis and Graves’ disease, underscores the need to examine the influence of modifiable dietary factors on thyroid pathophysiology. This narrative review aimed to evaluate current evidence on the role of nutrition—especially micronutrients such as iodine, selenium, iron, zinc, and vitamin D—in thyroid function and autoimmunity. A structured literature search was conducted using PubMed and Scopus to identify relevant human studies published between January 2002 and March 2025. A total of forty-one peer-reviewed articles were selected based on predefined inclusion criteria and assessed for scientific rigor and relevance. The evidence confirms the critical involvement of iodine and selenium in thyroid hormone synthesis and immune modulation, while iron and zinc were found to support enzymatic activity and endocrine stability. Vitamin D emerged as a potential immunoregulatory agent in autoimmune thyroid disease. Furthermore, certain macronutrients—including high-quality proteins, fiber, and omega-3 fatty acids—as well as dietary patterns such as the Mediterranean diet, were associated with favorable thyroid outcomes. Conversely, the intake of goitrogenic foods and soy isoflavones may necessitate caution in predisposed individuals. These findings highlight the relevance of individualized, evidence-based nutritional strategies as adjunctive approaches in the prevention and clinical management of thyroid disorders.
- 30 June 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 82, 60580
Open AccessImpact of Dietary Factors on Thyroid Function and Disorders
Thyroid health is intricately linked to nutritional status, as multiple micronutrients and dietary components modulate hormone biosynthesis, metabolism, and immune function. The increasing global prevalence of autoimmune thyroid disorders, particularly Hashimoto’s thyroiditis and Graves’ disease, underscores the need to examine the influence of modifiable dietary factors on thyroid pathophysiology. This narrative review aimed to evaluate current evidence on the role of nutrition—especially micronutrients such as iodine, selenium, iron, zinc, and vitamin D—in thyroid function and autoimmunity. A structured literature search was conducted using PubMed and Scopus to identify relevant human studies published between January 2002 and March 2025. A total of forty-one peer-reviewed articles were selected based on predefined inclusion criteria and assessed for scientific rigor and relevance. The evidence confirms the critical involvement of iodine and selenium in thyroid hormone synthesis and immune modulation, while iron and zinc were found to support enzymatic activity and endocrine stability. Vitamin D emerged as a potential immunoregulatory agent in autoimmune thyroid disease. Furthermore, certain macronutrients—including high-quality proteins, fiber, and omega-3 fatty acids—as well as dietary patterns such as the Mediterranean diet, were associated with favorable thyroid outcomes. Conversely, the intake of goitrogenic foods and soy isoflavones may necessitate caution in predisposed individuals. These findings highlight the relevance of individualized, evidence-based nutritional strategies as adjunctive approaches in the prevention and clinical management of thyroid disorders.
- Open Access
- 30 June 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 82, 60525
Gene Therapy and Down Syndrome: Can the future of Medicine bring a breakthrough?
Down syndrome (DS), or trisomy 21, is the most common chromosomal disorder, characterized by intellectual disability, congenital anomalies, and an increased risk of neurodegenerative diseases. This review synthesizes current knowledge on the etiology, clinical presentation, and modern therapeutic strategies for DS, including early intervention, medical management, and psychosocial support. Particular emphasis is placed on the revolutionary potential of CRISPR-Cas gene-editing technology as a tool for future treatment strategies. Drawing upon findings from many scientific publications, the article discusses the mechanism of CRISPR, its current medical applications, and its experimental use in silencing the extra chromosome 21 or correcting DS-associated genes. Technical, ethical, and delivery-related limitations are explored, alongside speculative but promising research directions, including base editing, prime editing, and cerebral organoids. The article concludes with a reflection on whether societal perceptions of genetic diversity should evolve alongside scientific innovation, highlighting that the greatest breakthrough may come not from altering genomes, but from fostering inclusion and understanding.
- 30 June 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 82, 60525
Open AccessGene Therapy and Down Syndrome: Can the future of Medicine bring a breakthrough?
Down syndrome (DS), or trisomy 21, is the most common chromosomal disorder, characterized by intellectual disability, congenital anomalies, and an increased risk of neurodegenerative diseases. This review synthesizes current knowledge on the etiology, clinical presentation, and modern therapeutic strategies for DS, including early intervention, medical management, and psychosocial support. Particular emphasis is placed on the revolutionary potential of CRISPR-Cas gene-editing technology as a tool for future treatment strategies. Drawing upon findings from many scientific publications, the article discusses the mechanism of CRISPR, its current medical applications, and its experimental use in silencing the extra chromosome 21 or correcting DS-associated genes. Technical, ethical, and delivery-related limitations are explored, alongside speculative but promising research directions, including base editing, prime editing, and cerebral organoids. The article concludes with a reflection on whether societal perceptions of genetic diversity should evolve alongside scientific innovation, highlighting that the greatest breakthrough may come not from altering genomes, but from fostering inclusion and understanding.